<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116384</article-id><article-id pub-id-type="publisher-id">ACM-43094</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_92172041.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血清HE4、血小板检测联合MRI对子宫内膜癌肌层浸润的研究进展
  Advances in Serum HE4 and Platelet Detection Combined with MRI in the Treatment of Endometrial Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>冬梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>苏荣</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>临沂市人民医院妇科，山东 临沂</addr-line></aff><aff id="aff2"><addr-line>山东第一医科大学，山东 济南</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>26256</fpage><lpage>2662</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  子宫内膜癌(EC)是女性生殖系统三大恶性肿瘤之一，近年来，其发病率及病死率有逐渐升高且呈年轻化趋势。准确评估浸润深度和术前分期对于子宫内膜癌患者是很重要的。作为新型的肿瘤标志物HE4，在早期EC诊断及预后中可以作为一个有用的血清学标记。血小板参数的改变可协助子宫内膜癌病情评估及预后判断。磁共振(MRI)检查在EC宫颈受累及肌层浸润深度有良好的敏感度与特异度。因此本文将对肿瘤标志物HE4、血小板参数及MRI在子宫内膜癌肌层浸润中的意义进行叙述。
   Endometrial cancer (EC) is one of the three malignant tumors of the female reproductive system. In recent years, its incidence and mortality have been increasing gradually and at a younger age. Accurate assessment of infiltration depth and preoperative staging is important for patients with endometrial cancer. As a novel tumor marker HE4, it can be used as a useful serological marker in early EC diagnosis and prognosis. The changes of platelet parameters can assist the assessment and prognosis of endometrial cancer. Magnetic resonance imaging (MRI) showed good sensitivity and specificity in EC cervical involvement and muscle infiltration depth. Therefore, the significance of tumor marker HE4, platelet parameters and MRI in muscular invasion of endometrial carcinoma will be described in this paper.
 
</p></abstract><kwd-group><kwd>子宫内膜癌，HE4，血小板，磁共振，肌层浸润, Endometrial Cancer</kwd><kwd> HE4</kwd><kwd> Platelet</kwd><kwd> MRI</kwd><kwd> Muscular Infiltration</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>子宫内膜癌(EC)是女性生殖系统三大恶性肿瘤之一，近年来，其发病率及病死率有逐渐升高且呈年轻化趋势。准确评估浸润深度和术前分期对于子宫内膜癌患者是很重要的。作为新型的肿瘤标志物HE4，在早期EC诊断及预后中可以作为一个有用的血清学标记。血小板参数的改变可协助子宫内膜癌病情评估及预后判断。磁共振(MRI)检查在EC宫颈受累及肌层浸润深度有良好的敏感度与特异度。因此本文将对肿瘤标志物HE4、血小板参数及MRI在子宫内膜癌肌层浸润中的意义进行叙述。</p></sec><sec id="s2"><title>关键词</title><p>子宫内膜癌，HE4，血小板，磁共振，肌层浸润</p></sec><sec id="s3"><title>Advances in Serum HE4 and Platelet Detection Combined with MRI in the Treatment of Endometrial Carcinoma</title><p>Dongmei Li<sup>1</sup>, Surong Wang<sup>2</sup></p><p><sup>1</sup>Shandong First Medical University, Jinan Shandong</p><p><sup>2</sup>Department of Gynecology, Linyi People’s Hospital, Linyi Shandong</p><p><img src="//html.hanspub.org/file/26-1572306x4_hanspub.png" /></p><p>Received: May 10<sup>th</sup>, 2021; accepted: May 29<sup>th</sup>, 2021; published: Jun. 11<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/26-1572306x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Endometrial cancer (EC) is one of the three malignant tumors of the female reproductive system. In recent years, its incidence and mortality have been increasing gradually and at a younger age. Accurate assessment of infiltration depth and preoperative staging is important for patients with endometrial cancer. As a novel tumor marker HE4, it can be used as a useful serological marker in early EC diagnosis and prognosis. The changes of platelet parameters can assist the assessment and prognosis of endometrial cancer. Magnetic resonance imaging (MRI) showed good sensitivity and specificity in EC cervical involvement and muscle infiltration depth. Therefore, the significance of tumor marker HE4, platelet parameters and MRI in muscular invasion of endometrial carcinoma will be described in this paper.</p><p>Keywords:Endometrial Cancer, HE4, Platelet, MRI, Muscular Infiltration</p><disp-formula id="hanspub.43094-formula29"><graphic xlink:href="//html.hanspub.org/file/26-1572306x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/26-1572306x7_hanspub.png" /> <img src="//html.hanspub.org/file/26-1572306x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>子宫内膜癌(endometrial carcinoma, EC)是发达国家最常见的妇科肿瘤 [<xref ref-type="bibr" rid="hanspub.43094-ref1">1</xref>]，来源于子宫内膜的上皮，分为雌激素依赖型(I型)和非雌激素依赖型(II型)，是女性生殖系统三大恶性肿瘤之一。据报道，2018年全球预计新发子宫内膜癌病例数为382,069例，新增死亡例数为89,929例 [<xref ref-type="bibr" rid="hanspub.43094-ref2">2</xref>]。子宫内膜癌的发病率有明确的地区差异，与地区的经济发达程度及饮食环境密切相关，在我国北京、广州等发达城市子宫内膜癌的发生率已经超过宫颈癌和卵巢癌，成为发病率最高的妇科恶性肿瘤。EC患者的高发年龄是50~60岁，近年来，其发病率及病死率有逐渐升高且呈年轻化趋势。在子宫内膜癌中，准确评估浸润深度和术前分期是很重要的 [<xref ref-type="bibr" rid="hanspub.43094-ref3">3</xref>]。目前大多数早期患者经手术治疗预后良好 [<xref ref-type="bibr" rid="hanspub.43094-ref4">4</xref>]，晚期EC因存在淋巴结转移治疗效果及预后欠佳。但若能早期诊断、及时治疗，I期低危型患者术后5年存活率可达80%~93% [<xref ref-type="bibr" rid="hanspub.43094-ref5">5</xref>]。</p></sec><sec id="s6"><title>2. 肿瘤标志物(Tumor Marker, TM)</title><sec id="s6_1"><title>2.1. 癌抗原(Carbohydrate Antigen, CA) 125</title><p>癌抗原(carbohydrate antigen, CA) 125、血小板增多和影像学对淋巴结转移的风险有很大和中等的影响，可以改善术前风险分层。临床早期子宫内膜癌的常规淋巴结切除术并不能改善预后，而且与手术相关的发病率为15%~20%，这就强调了改进术前风险分层的必要性。对癌症抗原125血清水平的测量、对血小板的评估和对淋巴结病的显像应该补充目前的术前风险分层 [<xref ref-type="bibr" rid="hanspub.43094-ref6">6</xref>]。超过75%的子宫内膜癌患者的死亡是由子宫内膜样子宫内膜癌引起的。早期诊断子宫内膜癌可增加治愈的机会，从而降低死亡率 [<xref ref-type="bibr" rid="hanspub.43094-ref7">7</xref>]。系统性淋巴结切除术可能导致术后并发症发生率升高，部分低危患者可不行淋巴结切除术，如高、中分化的子宫内膜样腺癌患者、病灶浸润浅肌层及宫腔病灶直径小于2 cm者 [<xref ref-type="bibr" rid="hanspub.43094-ref8">8</xref>]。</p></sec><sec id="s6_2"><title>2.2. HE (Human Epididymis Protein) 4</title><p>肿瘤标记物(tumor marker, TM)是由肿瘤细胞基因表达所产生，或者由人体对肿瘤细胞反应而产生，反映了肿瘤的存在和生长。HE (human epididymis protein) 4是最早发现于附睾远端的上皮细胞，在女性生殖系统上皮细胞中高表达。作为新型肿瘤标志物，HE4在早期卵巢癌病情监测以及诊断方面有较高的应用价值。有研究表明，HE4是检测EC患者的一种敏感的诊断血清标志物，且在早期EC诊断及预后中可以作为一个有用的标记，也用于监测治疗和发现早期复发 [<xref ref-type="bibr" rid="hanspub.43094-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.43094-ref10">10</xref>]。Li J等 [<xref ref-type="bibr" rid="hanspub.43094-ref11">11</xref>] 的meta分析表明，与CA125相比，血清HE4在未特别考虑分期和组织学类型的情况下，对所有EC病例的诊断具有更高的敏感性和总体准确性。</p><p>人附睾蛋白4水平与侵犯肌层厚度超过50%时的HE4值相比，侵犯肌层厚度超过50%时HE4值显著升高。随着肿瘤大小的增加，HE4水平显著升高。术前HE4评估可以帮助对深度浸润和(或)转移性疾病患者进行分层，并与其他相关的预后因素相关，以制定适当的手术策略 [<xref ref-type="bibr" rid="hanspub.43094-ref12">12</xref>]。方旖骅等 [<xref ref-type="bibr" rid="hanspub.43094-ref13">13</xref>] 报道，血清HE4对子宫内膜癌有良好的诊断价值，其诊断子宫内膜癌敏感度高于血清CA125，有利于降低漏诊率，可作为子宫内膜癌的筛查指标。子宫内膜癌患者血清HE4水平和FIGO分期、组织学分级、深肌层浸润有关，CA125、HE4表达水平与累及卵巢、分期、肌层浸润淋巴结转移相关。人附睾蛋白4在子宫内膜样子宫内膜癌患者是否需要进行淋巴结清扫的临床决策过程中可能是一个有用的术前标记。肿瘤标志物HE4是子宫内膜样子宫内膜癌女性子宫肌层侵犯深度的敏感标志物。在早期子宫内膜癌中，HE4可用于术前作为一种工具来帮助确定是否需要淋巴结切除术的女性 [<xref ref-type="bibr" rid="hanspub.43094-ref14">14</xref>]。目前普遍认为血清癌抗原125 (CA125)在子宫内膜癌的诊断中有重要作用，但在早期患者中升高并不显著，某些非肿瘤疾患CA125也有不同程度的升高，因此CA125对子宫内膜癌诊断的灵敏度和特异度不高 [<xref ref-type="bibr" rid="hanspub.43094-ref15">15</xref>]。姜伟丽等 [<xref ref-type="bibr" rid="hanspub.43094-ref16">16</xref>] 报道，子宫内膜癌患者中，不同肌层浸润深度者间血清HE4及CA125含量存在明显差异，且随着浸润深度增加，其血清含量呈增高趋势，HE4及CA125与肌层浸润深度呈明显正相关关系。HE4及CA125可用于评估子宫内膜癌肌层浸润深度，为临床制定、调整治疗方案提供参考依据。</p></sec></sec><sec id="s7"><title>3. 血小板(Platelet, PLT)参数</title><sec id="s7_1"><title>3.1. 血小板(PLT)</title><p>在肺癌、结直肠癌、原发性肝癌、口腔癌等患者中PLT水平明显升高，升高的PLT与肿瘤细胞侵袭和转移相关。1872年Riess首次发现血小板(Platelet, PLT)是肿瘤进展、转移和肿瘤相关血栓形成的关键因素。Song J等 [<xref ref-type="bibr" rid="hanspub.43094-ref17">17</xref>] 报道，恶性子宫内膜癌患者术前血小板形态参数及其他全血细胞与良性疾病的进行比较，具体包括术前的白细胞(WBC)、血红蛋白、血小板计数(PLT)、血小板分布宽度(PDW)、平均血小板体积(MPV)和血小板压积(PCT)，计算中性粒细胞–淋巴细胞比(NLR)和血小板–淋巴细胞比(PLR)。对于恶性肿瘤，进一步收集Ki-67百分比和孕激素受体(PR)状态。确诊子宫内膜癌患者的PDW值明显降低，MPV显著升高。进一步分析子宫内膜癌患者，血小板参数在I~II期和III~IV期患者间无显著差异，而PR阴性患者的PDW值较阳性患者升高，MPV值降低。术前血小板形态参数可作为鉴别子宫内膜良恶性的一种预测因素。中性粒细胞/淋巴细胞比率(NLR)、单核细胞计数(MC)、和血小板/淋巴细胞比率(NLR)在疾病的晚期有统计学意义，但只有单核细胞计数在级别上有统计学意义。较高的中性粒细胞/淋巴细胞比率和血小板/淋巴细胞比率被发现与疾病的晚期、深部肌层侵犯、颈部受累、淋巴血管间隙(LVSI)和淋巴结受累有关。发现NLR是生存的预后因素。在子宫内膜癌中，NLR和PLR值对于淋巴结侵犯和宫颈侵犯的有预测价值 [<xref ref-type="bibr" rid="hanspub.43094-ref18">18</xref>]。在Pergialiotis V等 [<xref ref-type="bibr" rid="hanspub.43094-ref19">19</xref>] 荟萃分析中，子宫内膜癌患者的NLR值显著升高。此外，PLR和NLR值在晚期疾病患者中升高。术前血小板(PLT)、血小板分布宽度(PDW)与血小板与淋巴细胞的比值(PLR)的值对子宫内膜癌具有一定的诊断价值，三者联合的诊断效能更高，且其与子宫内膜癌的脉管浸润及宫颈间质浸润有关。术前PDW、PLR的值与子宫内膜癌术后病理分期相关 [<xref ref-type="bibr" rid="hanspub.43094-ref20">20</xref>]。</p></sec><sec id="s7_2"><title>3.2. PLT的预测意义</title><p>血小板参数可能对子宫内膜癌具有预测价值。术前PLT、PDW及MPV水平在正常子宫内膜、子宫内膜增生及子宫内膜癌中呈增高趋势，且术前PDW、MPV有助于预测子宫内膜癌的进展程度 [<xref ref-type="bibr" rid="hanspub.43094-ref21">21</xref>]。EC中III期及IV期患者血清中PLT、MPV、PDW、PCT水平均较I期及II期高，差异有统计学意义(P &lt; 0.05)。存在盆腔淋巴结转移组血清中PLT、MPV、PDW、PCT水平较无淋巴结转移组高(P &lt; 0.05)。子宫肌层浸润深度 ≥ 1/2组血清中PLT、MPV、PDW、PCT水平较浸润深度 &lt; 1/2组高(P &lt; 0.05)。血小板数量增多及功能活化与子宫内膜癌的侵袭转移关系密切，血小板参数的改变可协助子宫内膜癌病情评估及预后判断 [<xref ref-type="bibr" rid="hanspub.43094-ref22">22</xref>]。EC患者外周血与血清CA125水平呈正相关，两者一致性好 [<xref ref-type="bibr" rid="hanspub.43094-ref23">23</xref>]。</p></sec></sec><sec id="s8"><title>4. 影像学在EC中的应用</title><p>随着影像诊断技术逐步提高，MRI在各种妇科恶性肿瘤的早期诊断发挥重要作用。在子宫内膜癌中，准确评估浸润深度和术前分期是很重要的。盆、腹腔磁共振增强扫描可用于评估子宫内膜癌肌层及宫颈浸润、子宫外累及后腹膜淋巴结转移情况。磁共振(MRI)检查在EC宫颈受累及肌层浸润深度有良好的敏感度与特异度，可以对肿瘤的直径、性质、肌层浸润及淋巴结转移情况有多方位、多角度、多平面的成像，在EC术前诊断、评估及治疗方案的制定中有重要的意义。在Yin XH等 [<xref ref-type="bibr" rid="hanspub.43094-ref24">24</xref>] 报道，在深部肌层浸润(&gt;50%)的评估中，MRI的敏感性为70.00%，特异度为94.87%，阳性预测值为77.78%，阳性预测值为92.50%，阳性预测值为13.65，阴性似然比为0.316。MRI是诊断子宫肌层侵犯和宫颈侵犯的较好方法。增强MRI是术前评估肌层浸润情况的重要影像学依据。使用T2WI-DWI对子宫内膜癌的子宫肌层侵犯和分期的有效评估可能是一种无创的、低成本的方法 [<xref ref-type="bibr" rid="hanspub.43094-ref3">3</xref>]。MRI检查有助于临床医生准确判断淋巴结是否存在转移现象以及子宫内膜癌是否侵犯宫颈。术前为患者实施MRI、HE4检测并结合子宫内膜活检结果对病情进行综合评估，对降低患者早期盆腔淋巴结清扫率，缩短手术时间，缩小手术范围，减少术后相关并发症均具有重要的应用价值。MRI有助于临床医生对子宫肌层浸润深度以及肿瘤分期进行准确评估，为术前常用辅助检查工具 [<xref ref-type="bibr" rid="hanspub.43094-ref25">25</xref>]。1988年，国际妇产科联盟(International Federation on Gynecology and Obstetrics, FIGO)系统将子宫内膜癌的分期由临床分期改为手术分期。此外，美国妇产医师学会目前提倡系统手术，美国国家综合癌症网络(National Comprehensive Cancer, NCCN)及FIGO指南均采用第8版美国癌症联合委员会(American Joint Committee on Cancer, AICC) TNM分期和FIGO 2019分期。早期子宫内膜癌的标椎治疗是筋膜外全子宫双附件切除术 + 淋巴结评估。对于晚期或转移性患者行姑息性手术 + 放化疗的综合治疗。尽管分期手术需要进行淋巴结清扫，但是否行盆腔和腹主动脉旁淋巴结清扫扔存在争议。盆腔和(或)腹主动脉淋巴结评估是手术分期的重要的内容，对于预后和是否继续辅助治疗提供依据。早期低危患者的淋巴结转移率低，并且淋巴结切除与未行淋巴结切除在无疾病生存和总生存无明显差异，患者的生存没有显著的获益，对于早期低危的患者可以不常规行淋巴结切除，特别是肌层无浸润的子宫内膜样癌。但是对于中高危型子宫内膜癌患者，淋巴结转移率高，术中应行盆腔淋巴结及腹主动脉旁淋巴结切除，范围上界至肾静脉水平。</p></sec><sec id="s9"><title>5. 术前肌层浸润的评估</title><p>系统性淋巴结切除可能导致手术风险和术后并发症的发生率的增加，如淋巴囊肿、尿潴留、肠梗阻、深静脉血栓形成、盆腔感染、神经损伤、血管损伤，和输血的必要性。谢玲玲等 [<xref ref-type="bibr" rid="hanspub.43094-ref8">8</xref>] 报道，低危的EC患者(内膜样腺癌I期，G<sub>1-2</sub>，病灶局限于内膜层或浅肌层浸润)，可行淋巴结活检。有研究显示，低危病人淋巴结的转移率为2.4%。高危患者(如深肌层浸润、高级别癌、浆液性癌、透明细胞癌、和癌肉瘤)需要系统切除腹主动脉旁淋巴结达肾血管水平。术前根据肌层浸润的深度分级，避免不必要的淋巴结切除术对低风险患者很重要。深肌层浸润患者需要进行淋巴结清扫，若患者合并症较多，不能耐受长时间的手术及淋巴结清扫引起的并发症，可根据术前的肌层浸润评估结果，制定针对性的治疗方案。因此，术前准确的肌层浸润诊断具有重要价值。在有关报道中，对于子宫内膜癌患者，不同肌层浸润深度间血清HE4及CA125含量存在有明显的差异，并且随着浸润深度的增加，其血清中含量也是逐渐增高的，HE4及CA125与肌层浸润均呈正相关关系。</p></sec><sec id="s10"><title>6. 联合检测指标</title><p>血清CA125和HE4是评估子宫内膜癌病情进展情况的重要指标，CA125和HE4联合盆腔MR检查可提高子宫内膜癌诊断的灵敏度和特异性，具有重要的临床参考价值 [<xref ref-type="bibr" rid="hanspub.43094-ref15">15</xref>]。关于肌层侵犯，MRI和经阴道超声(TVS)在术前检测方面具有可比性。Angioli R等 [<xref ref-type="bibr" rid="hanspub.43094-ref26">26</xref>] 报道，关于宫颈浸润，TVS和HE4之间的相关性具有更好的术前诊断有效性(TVS + HE4的诊断有效性为96.3，MRI为91%，TVS为85%)。高分期、深层肌层侵犯、淋巴结或宫颈间质侵犯可提高MRI诊断的准确性。高水平的HE4和CA125在深度肌层侵犯和高级别肿瘤患者中观察到 [<xref ref-type="bibr" rid="hanspub.43094-ref27">27</xref>]。</p></sec><sec id="s11"><title>7. 确诊的“金标准”——术后常规病理</title><p>子宫内膜癌可以通过子宫内膜活检获得病理确诊，但宫腔镜检查和分段诊刮需要妇科医生经过严格的培训并具有丰富的经验，并且均为有创性检查。传统的实验室和影像学诊断方法是依靠肿瘤标志物CA125和彩超判断，但灵敏度和特异度均不高，可能会引起漏诊或误诊。如何获得更多可靠信息以选择治疗方案及手术方式，指导预后和随访一直是临床研究的热点。王安娜等 [<xref ref-type="bibr" rid="hanspub.43094-ref28">28</xref>] 报道，CA125、HE4在子宫内膜癌的诊断上具有优势，两者的表达水平与子宫内膜癌累及卵巢、分期、肌层浸润、淋巴结转移有关；CA125 + HE4 + 增强MRI联合检查诊断子宫内膜癌深肌层浸润的效能要高于单独检查。盆腔磁共振成像检查联合血清HE4水平检测可显著提升子宫内膜癌诊断准确度及敏感度，减少漏诊情况，且能为疾病分期评估提供可靠依据 [<xref ref-type="bibr" rid="hanspub.43094-ref29">29</xref>]。晚期子宫内膜癌组的血清CA125、HE4水平明显高于早期子宫内膜癌组，提示血清中CA125、HE4的浓度随手术病理分期的增高呈上升趋势，对于临床分期的诊断具有重要参考价值 [<xref ref-type="bibr" rid="hanspub.43094-ref15">15</xref>]。</p></sec><sec id="s12"><title>8. 结论</title><p>综上，血液学指标及影像学联合检测是现研究的新趋势，可提高诊断的灵敏度，采用联合诊断可起到优势互补作用，弥补单一方法诊断的缺陷，对于筛选高危患者提供更多参考信息。血清HE4、血小板检测及MRI是子宫内膜癌术前分期的无创诊断方法，评估子宫内膜癌患者深肌层浸润情况对临床分期十分重要，患者的手术治疗以及预后情况密切相关。MRI扫描对子宫内膜癌患者深肌层浸润情况评估具有较高诊断价值 [<xref ref-type="bibr" rid="hanspub.43094-ref30">30</xref>]。因此进一步明确血清HE4、血小板检测联合MRI在子宫内膜癌肌层浸润诊断的准确度及敏感度，可以为疾病的分期评估、临床制定及调整治疗提供参考依据，使得EC患者得到更多的获益。</p></sec><sec id="s13"><title>文章引用</title><p>李冬梅,王苏荣. 血清HE4、血小板检测联合MRI对子宫内膜癌肌层浸润的研究进展Advances in Serum HE4 and Platelet Detection Combined with MRI in the Treatment of Endometrial Carcinoma[J]. 临床医学进展, 2021, 11(06): 26256-2662. https://doi.org/10.12677/ACM.2021.116384</p></sec><sec id="s14"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43094-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Colombo, N., Creutzberg, C., Amant, F., et al. (2016) ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-Up. Annals of Oncology, 27, 16-41. &lt;br&gt;https://doi.org/10.1093/annonc/mdv484</mixed-citation></ref><ref id="hanspub.43094-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.  
&lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.43094-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Guo, Y., Wang, P., Wang, P., et al. (2017) Myometrial Invasion and Overall Staging of Endometrial Carcinoma: Assessment Using Fusion of T2-Weighted Magnetic Resonance Imaging and Diffusion-Weighted Magnetic Resonance Imaging. OncoTargets and Therapy, 10, 5937-5943. &lt;br&gt;https://doi.org/10.2147/OTT.S145763</mixed-citation></ref><ref id="hanspub.43094-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Jingjing, H., Rui, J. and Hui, P. (2019) Adjuvant Chemoradiotherapy vs. Radiotherapy Alone in Early-Stage High-Risk Endometrial Cancer: A Systematic Review and Meta-Analysis. European Review for Medical and Pharmacological Sciences, 23, 833-840.</mixed-citation></ref><ref id="hanspub.43094-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">包媛媛, 洛若愚. 子宫内膜癌早期筛查与诊断研究进展[J]. 医学综述, 2020, 26(1): 76-80+85.</mixed-citation></ref><ref id="hanspub.43094-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Reijnen, C., IntHout, J., Massuger, L., et al. (2019) Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis. Oncologist, 24, e880-e890. &lt;br&gt;https://doi.org/10.1634/theoncologist.2019-0117</mixed-citation></ref><ref id="hanspub.43094-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Bagaria, M., Shields, E. and Bakkum-Gamez, J.N. (2017) Novel Approaches to Early Detection of Endometrial Cancer. Current Opinion in Obstetrics and Gynecology, 29, 40-46. &lt;br&gt;https://doi.org/10.1097/GCO.0000000000000332</mixed-citation></ref><ref id="hanspub.43094-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">谢玲玲, 林荣春, 林仲秋. 国际权威子宫内膜癌诊治指南解读[J]. 实用妇产科杂志, 2020, 36(6): 428-432.</mixed-citation></ref><ref id="hanspub.43094-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Dewan, R., Dewan, A., Hare, S., Bhardwaj, M. and Mehrotra, K. (2017) Diagnostic Performance of Serum Human Epididymis Protein 4 in Endometrial Carcinoma: A Pilot Study. Journal of Clinical and Diagnostic Research, 11, XC01-XC05. &lt;br&gt;https://doi.org/10.7860/JCDR/2017/28926.10285</mixed-citation></ref><ref id="hanspub.43094-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hu, L., Du, S., Guo, W., Chen, D. and Li, Y. (2016) Comparison of Serum Human Epididymis Protein 4 and Carbohydrate Antigen 125 as Markers in Endometrial Cancer: A Meta-Analysis. International Journal of Gynecological Cancer, 26, 331-340. &lt;br&gt;https://doi.org/10.1097/IGC.0000000000000621</mixed-citation></ref><ref id="hanspub.43094-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Wang, X., Qu, W., Wang, J. and Jiang, S.W. (2019) Comparison of Serum Human Epididymis Protein 4 and CA125 on Endometrial Cancer Detection: A Meta-Analysis. Clinica Chimica Acta, 488, 215-220.  
&lt;br&gt;https://doi.org/10.1016/j.cca.2018.11.011</mixed-citation></ref><ref id="hanspub.43094-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Fanfani, F., Restaino, S., Cicogna, S., et al. (2017) Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study. International Journal of Gynecological Cancer, 27, 1200-1205.  
&lt;br&gt;https://doi.org/10.1097/IGC.0000000000001015</mixed-citation></ref><ref id="hanspub.43094-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">方旖骅, 颜士杰. 血清人附睾蛋白4检测对子宫内膜癌诊断的临床意义[J]. 安徽医学, 2015, 36(9): 1068-1071.</mixed-citation></ref><ref id="hanspub.43094-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bignotti, E., Ragnoli, M., Zanotti, L., et al. (2011) Diagnostic and Prognostic Impact of Serum HE4 Detection in Endometrial Carcinoma Patients. British Journal of Cancer, 104, 1418-1425. &lt;br&gt;https://doi.org/10.1038/bjc.2011.109</mixed-citation></ref><ref id="hanspub.43094-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">刘若男, 苏宁, 侯艺芳, 李秀荣, 曲金荣, 王莉. 血清CA125和HE4联合盆腔MR检查在子宫内膜癌中的临床意义[J]. 医药论坛杂志, 2016, 37(9): 18-20.</mixed-citation></ref><ref id="hanspub.43094-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">姜伟丽. 血清人附睾分泌蛋白4、糖类抗原125与子宫内膜癌肌层浸润深度的相关性分析[J]. 中国民康医学, 2018, 30(6): 45-46.</mixed-citation></ref><ref id="hanspub.43094-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Song, J., Lai, X., Zhang, Y., Zheng, X. and Su, J. (2019) Preoperative Platelet Morphology Parameters as Prognostic Predictors for Endometrial Malignant Carcinoma Stage and Progesterone Receptor. Medicine (Baltimore), 98, e17818.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000017818</mixed-citation></ref><ref id="hanspub.43094-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Temur, I., Kucukgoz Gulec, U., Paydas, S., Guzel, A., Sucu, M. and Vardar, M.A. (2018) Prognostic Value of Pre-Operative Neutrophil/Lymphocyte Ratio, Monocyte Count, Mean Platelet Volume, and Platelet/Lymphocyte Ratio in Endometrial Cancer. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology, 226, 25-29.  
&lt;br&gt;https://doi.org/10.1016/j.ejogrb.2018.05.028</mixed-citation></ref><ref id="hanspub.43094-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Pergialiotis, V., Oikonomou, M., Damaskou, V., et al. (2018) Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratio as Predictive Indices of Endometrial Carcinoma: Findings from a Retrospective Series of Patients and Meta-Analysis. Journal of Gynecology Obstetrics and Human Reproduction, 47, 511-516.  
&lt;br&gt;https://doi.org/10.1016/j.jogoh.2018.08.016</mixed-citation></ref><ref id="hanspub.43094-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">李萌萌. 术前血小板参数对子宫内膜癌的诊断价值及与临床病理特征的相关性分析[D]: [硕士学位论文]. 延吉: 延边大学, 2019.</mixed-citation></ref><ref id="hanspub.43094-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">窦倩如, 张晓敏, 刘芹, 王璇, 张英姿. 血小板参数与子宫内膜增生及子宫内膜癌的关系[J]. 现代妇产科进展, 2019, 28(4): 279-282.</mixed-citation></ref><ref id="hanspub.43094-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">蔡东阁, 赵刚, 赵晓桂, 闫桂花, 王倩. 子宫内膜癌患者不同病期血小板参数变化及其临床意义[J]. 山西医科大学学报, 2016, 47(4): 377-380.</mixed-citation></ref><ref id="hanspub.43094-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">李碧岚, 王晓珺, 黄宇佳, 叶磊, 严沁, 万小平. 联合检测血小板和CA125对子宫内膜癌的诊断价值[J]. 江苏医药, 2020, 46(7): 676-680.</mixed-citation></ref><ref id="hanspub.43094-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Yin, X.H., Jia, H.Y., Shi, M., Wu, H. and Li, Y.M. (2015) Magnetic Resonance Imaging for Detection of Depth of Myometrial Invasion and Cervical Invasion in Patients with Endometrial Carcinoma. International Journal of Clinical and Experimental Medicine, 8, 19501-19505.</mixed-citation></ref><ref id="hanspub.43094-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">张智, 陈红霞, 徐晓霞. 血清人附睾蛋HE4、CA125、CA199联合诊断子宫内膜癌的价值[J]. 实用医学杂志, 2016, 32(7): 1108-1111.</mixed-citation></ref><ref id="hanspub.43094-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Angioli, R., Plotti, F., Capriglione, S., et al. (2016) Preoperative Local Staging of Endometrial Cancer: The Challenge of Imaging Techniques and Serum Biomarkers. Archives of Gynecology and Obstetrics, 294, 1291-1298.  
&lt;br&gt;https://doi.org/10.1007/s00404-016-4181-z</mixed-citation></ref><ref id="hanspub.43094-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Zamani, N., Modares Gilani, M., Zamani, F. and Zamani, M.H. (2015) Utility of Pelvic MRI and Tumor Markers HE4 and CA125 to Predict Depth of Myometrial Invasion and Cervical Involvement in Endometrial Cancer. Journal of Family and Reproductive Health, 9, 177-183.</mixed-citation></ref><ref id="hanspub.43094-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">王安娜, 兰雪玲, 龙再秋. 人附睾蛋白4、糖类抗原125、增强MRI单独及联合检查对子宫内膜癌深肌层浸润诊断价值研究[J]. 临床军医杂志, 2020, 48(6): 691-694.</mixed-citation></ref><ref id="hanspub.43094-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">王恩力, 周坤, 刘淑梅, 任建新. 盆腔磁共振成像检查联合血清人附睾蛋白4水平检测对子宫内膜癌患者诊断效能的影响[J]. 广东医学, 2019, 40(20): 2886-2889.</mixed-citation></ref><ref id="hanspub.43094-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">施俊进, 康书朝, 徐鹏鹏. MRI检测方法在评估子宫内膜癌患者深肌层浸润中的作用[J]. 全科医学临床与教育, 2018, 16(6): 677-679.</mixed-citation></ref></ref-list></back></article>